Discover & Develop Selective, Clinically Validated & Novel Covalent Therapeutics to Expand the Targetable Proteome & Non-Cystine Amino Acid Space in Oncology, Immunology & Beyond The covalency renaissance continues as […]

With recent accelerated approval wins, positive clinical trial readouts, progression through clinical pipelines and exciting mergers and acquisitions, it has certainly been an industry-defining year for the rare and genetic […]

With Remix Therapeutics joining forces with Roche and Daiichi Sankyo partnering with Depixus, there have been many valuable collaborations entering the RNA-targeting field, accelerating efficacious and selective small molecules targeting […]

With the community hailing the latest FDA-approved therapeutic with Novartis’ inhibitor of the alternative complement for PNH, which inhibitor will be the next to harness the complement system for the […]

The 4th ADC Target Selection Summit returns to outline approaches to identify and validate novel targets that can be clinically and commercially successful and discuss rationale behind selecting a target […]

Join industry leaders like Eli Lilly, Merck, Novo Nordisk and Pfizer at the 4th Applied Biocatalysis & Enzyme Engineering Summit (December 10-12, 2024 – Philadelphia, PA). This is your perfect moment to […]